Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melvin Wagner

Ophthalmology Carlisle, PA Medical Doctor

NPI 1013943950 CMS profile 677289

338 Alexander Spring Rd, Carlisle, PA 17015

Open in the dashboard

General payments

$5,074

190 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melvin Wagner of Carlisle, PA is reported in the CMS Open Payments database as having received $5,074 across 190 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $933 33
2024 General $1,993 40
2023 General $556 35
2022 General $662 29
2021 General $440 23
2020 General $170 11
2019 General $320 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melvin Wagner
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Melvin Wagner were reported at $933. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Melvin Wagner Ophthalmology median Middle half National median
2019 $320 $258 $104–$655 $163
2020 $170 $126 $45–$321 $114
2021 $440 $205 $76–$534 $132
2022 $662 $266 $100–$678 $149
2023 $556 $308 $117–$745 $160
2024 $1,993 $340 $127–$846 $164
2025 $933 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,176 58 payments
  2. Regeneron Healthcare Solutions, Inc. $454 18 payments
  3. Bausch & Lomb Americas Inc. $425 19 payments
  4. AbbVie, Inc. $324 13 payments
  5. Sun Pharmaceutical Industries Inc. $282 13 payments
  6. Novartis Pharmaceuticals Corporation $257 17 payments
  7. Mallinckrodt Hospital Products Inc. $231 6 payments
  8. Genentech USA, Inc. $123 6 payments
  9. Allergan Inc. $98 6 payments
  10. RxSight Inc $75 3 payments
  11. Other $630 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,829 185 payments
  2. Travel and Lodging $1,187 2 payments
  3. Education $58 3 payments
Products named General payments · program years 2019–2025
  1. EYLEA HD $384 15 payments
  2. Cequa $265 12 payments
  3. XIIDRA $242 15 payments
  4. ACTHAR $231 6 payments
  5. MIEBO $189 5 payments
  6. Clareon Ophthalmology $180 14 payments
  7. VYZULTA $174 10 payments
  8. AcrySof IQ VIVITY IOL $157 2 payments
  9. Clareon Ophthalmology $145 2 payments
  10. LUMIGAN $140 6 payments
  11. Other $2,437 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,822

Median for Ophthalmology: 891

Drug cost

$503,130

Median for Ophthalmology: $68,233

Branded share of claims

45.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 343 $143,929
Restasis Cyclosporine Brand 73 $97,425
Xiidra Lifitegrast Brand 58 $67,697
Cyclosporine Generic 66 $45,584
Combigan Brimonidine Tartrate/Timolol Brand 71 $23,269
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 116 $17,879
Doxycycline Hyclate Generic 369 $11,986
Prednisolone Acetate Generic 296 $11,673
Travoprost Generic 63 $10,965
Simbrinza Brinzolamide/Brimonidine Tart Brand 36 $10,674

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$915,545

Of which drugs: $457,946

Medicare patients

1,513

Average age 77

Services billed

8,198

918 women, 595 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 43%
Diabetes 27%
Ischemic heart disease 25%
Chronic kidney disease 24%
Atrial fibrillation 19%
Depression 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 67 597 $387,097
Injection, faricimab-svoa, 0.1 mg J2777 Office 11 1,980 $54,080

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $246
$246 — —
VABYSMO
  • Genentech USA, Inc. $58
$58 — 1,980
Cequa
  • Sun Pharmaceutical Industries Inc. $51
$51 — —
LUMIGAN
  • AbbVie, Inc. $46
$46 343 —
Izervay
  • Astellas Pharma US Inc $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

190 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record